Colchicine Dosing in Pericarditis
For acute pericarditis in adults, use colchicine 0.5 mg twice daily if body weight ≥70 kg or 0.5 mg once daily if <70 kg for 3 months; for recurrent pericarditis, use the same weight-based dosing for at least 6 months. 1
Adult Dosing Algorithm
Acute Pericarditis (First Episode)
- Weight ≥70 kg: 0.5 mg twice daily for 3 months 1
- Weight <70 kg: 0.5 mg once daily for 3 months 1
- Key point: Colchicine is added on top of aspirin or NSAIDs, not as monotherapy 1
- Tapering: Not mandatory, but if desired, reduce to 0.5 mg every other day (<70 kg) or 0.5 mg once daily (≥70 kg) in the final weeks 1
Recurrent Pericarditis
- Weight ≥70 kg: 0.5 mg twice daily for ≥6 months 1
- Weight <70 kg: 0.5 mg once daily for ≥6 months 1
- Critical difference: Use no loading dose for recurrent pericarditis 1
- Tapering: Not necessary, but alternatively 0.5 mg every other day (<70 kg) or 0.5 mg once daily (≥70 kg) in final weeks 1
The evidence strongly supports this weight-based approach, with the ICAP trial demonstrating a 56% relative risk reduction in recurrent pericarditis when colchicine was added to conventional therapy 2. The CORP trial showed similar efficacy for secondary prevention 3.
Renal Impairment Adjustments
Mild to Moderate Renal Impairment (CrCl 30-80 mL/min)
Severe Renal Impairment (CrCl <30 mL/min)
Dialysis Patients
Critical caveat: The FDA label provides these adjustments primarily for gout and FMF, but the same principles apply to pericarditis given colchicine's narrow therapeutic window 4.
Hepatic Impairment Adjustments
Mild to Moderate Hepatic Impairment
Severe Hepatic Impairment
Pediatric Dosing
The ESC guidelines do not provide specific pediatric dosing recommendations for pericarditis. [1-1 However, one case report described successful use of 1 mg/day in a 2-year-old girl (approximately 100 mg/kg/day equivalent) for large pericardial effusion 5. This represents a significant evidence gap, and pediatric dosing should be extrapolated cautiously from adult weight-based recommendations or FMF dosing guidelines.
Drug Interaction Adjustments
Strong CYP3A4 Inhibitors (e.g., clarithromycin, ketoconazole)
When used with protease inhibitors or other strong CYP3A4 inhibitors:
- Reduce to: 0.3 mg once daily (from 0.6 mg twice daily) 4
- Or: 0.3 mg every other day (from 0.6 mg once daily) 4
- Contraindication: Do not use if patient has renal or hepatic impairment 4
P-glycoprotein Inhibitors (e.g., cyclosporine, ranolazine)
- Reduce to: 0.3 mg once daily (from 0.6 mg twice daily) 4
- Or: 0.3 mg every other day (from 0.6 mg once daily) 4
CYP3A4 Inducers (e.g., carbamazepine, rifampin)
- Problem: May render colchicine ineffective by increasing clearance 6
- Solution: Consider therapeutic drug monitoring or alternative anti-inflammatory strategies 6
- This is an underappreciated interaction that can lead to treatment failure 6
Common Pitfalls to Avoid
Using loading doses in recurrent pericarditis: The guidelines explicitly state to use weight-adjusted doses without a loading dose for recurrent disease 1. This differs from acute gout treatment.
Combining colchicine with strong CYP3A4 inhibitors in renal/hepatic disease: This combination is absolutely contraindicated and can cause fatal toxicity 4.
Premature discontinuation: The minimum duration is 3 months for acute pericarditis and 6 months for recurrent pericarditis 1. Shorter courses increase recurrence risk.
Using corticosteroids first-line: Corticosteroids are not recommended as first-line therapy (Class III recommendation) because they favor chronicity and recurrence 1. Colchicine + NSAIDs is the evidence-based approach.
Ignoring gastrointestinal intolerance: Approximately 10% of patients experience GI side effects 7, 8. Temporary dose reduction or brief discontinuation usually resolves this without requiring permanent cessation.
Overlooking CYP3A4 inducers: Unlike inhibitors, inducers like carbamazepine can cause treatment failure by reducing colchicine levels 6. This requires either dose adjustment or alternative therapy.